BACKGROUND: As moderate to severe psoriasis is a systemic disease with large effects on health-related quality of life, generic measures that include overall health, not only skin involvement, are necessary. Knowledge about the relationship between the generic preference-based EuroQol 5D (EQ-5D) and dermatology-specific measures in psoriasis is limited. OBJECTIVES: To analyse EQ-5D, the Dermatology Life Quality Index (DLQI) and the Psoriasis Area and Severity Index (PASI) in patients with moderate to severe psoriasis in Swedish clinical practice by demographic characteristics, to compare EQ-5D among patients vs. Swedish population values, and to analyse the relationships between EQ-5D, DLQI and PASI. METHODS: This observational cohort study was based on PsoReg, the Swedish National Registry for Systemic Treatment of Psoriasis. EQ-5D was compared among patients with psoriasis vs. a defined general population in Sweden, retrieved from a previous study. Relationships between measures were examined with correlation tests and regression analysis. RESULTS: In total, 2450 patients (1479 men and 971 women) were included. Median EQ-5D, DLQI and PASI scores were 0·769, 4 and 4·7, respectively. Patients with psoriasis had a significantly lower EQ-5D compared with the defined general population. EQ-5D correlated moderately with DLQI (-0·55) and weakly with PASI (-0·25) (P < 0·001). CONCLUSIONS: When assessing psoriasis treatments and making decisions about treatment guidelines and resource allocation, EQ-5D, DLQI and PASI provide a useful set of complementary tools, answering to different needs. If EQ-5D is not included in the original trial the second-best option in cost-effectiveness studies is to use mapping between DLQI and EQ-5D.
BACKGROUND: As moderate to severe psoriasis is a systemic disease with large effects on health-related quality of life, generic measures that include overall health, not only skin involvement, are necessary. Knowledge about the relationship between the generic preference-based EuroQol 5D (EQ-5D) and dermatology-specific measures in psoriasis is limited. OBJECTIVES: To analyse EQ-5D, the Dermatology Life Quality Index (DLQI) and the Psoriasis Area and Severity Index (PASI) in patients with moderate to severe psoriasis in Swedish clinical practice by demographic characteristics, to compare EQ-5D among patients vs. Swedish population values, and to analyse the relationships between EQ-5D, DLQI and PASI. METHODS: This observational cohort study was based on PsoReg, the Swedish National Registry for Systemic Treatment of Psoriasis. EQ-5D was compared among patients with psoriasis vs. a defined general population in Sweden, retrieved from a previous study. Relationships between measures were examined with correlation tests and regression analysis. RESULTS: In total, 2450 patients (1479 men and 971 women) were included. Median EQ-5D, DLQI and PASI scores were 0·769, 4 and 4·7, respectively. Patients with psoriasis had a significantly lower EQ-5D compared with the defined general population. EQ-5D correlated moderately with DLQI (-0·55) and weakly with PASI (-0·25) (P < 0·001). CONCLUSIONS: When assessing psoriasis treatments and making decisions about treatment guidelines and resource allocation, EQ-5D, DLQI and PASI provide a useful set of complementary tools, answering to different needs. If EQ-5D is not included in the original trial the second-best option in cost-effectiveness studies is to use mapping between DLQI and EQ-5D.
Authors: Adrienn Katalin Poór; Fanni Rencz; Valentin Brodszky; László Gulácsi; Zsuzsanna Beretzky; Bernadett Hidvégi; Péter Holló; Sarolta Kárpáti; Márta Péntek Journal: Qual Life Res Date: 2017-09-05 Impact factor: 4.147
Authors: Laura M Sawyer; David Wonderling; Karina Jackson; Ruth Murphy; Eleanor J Samarasekera; Catherine H Smith Journal: Pharmacoeconomics Date: 2015-02 Impact factor: 4.981
Authors: M Augustin; S Abeysinghe; U Mallya; A Qureshi; N Roskell; D McBride; C Papavassillis; J Gelfand Journal: J Eur Acad Dermatol Venereol Date: 2015-12-10 Impact factor: 6.166
Authors: Kate Breckenridge; Hillary L Bekker; Elizabeth Gibbons; Sabine N van der Veer; Denise Abbott; Serge Briançon; Ron Cullen; Liliana Garneata; Kitty J Jager; Kjersti Lønning; Wendy Metcalfe; Rachael L Morton; Fliss E M Murtagh; Karl Prutz; Susan Robertson; Ivan Rychlik; Steffan Schon; Linda Sharp; Elodie Speyer; Francesca Tentori; Fergus J Caskey Journal: Nephrol Dial Transplant Date: 2015-05-16 Impact factor: 5.992
Authors: Faraz Mahmood Ali; Richard Kay; Andrew Y Finlay; Vincent Piguet; Joerg Kupfer; Florence Dalgard; M Sam Salek Journal: Qual Life Res Date: 2017-06-10 Impact factor: 4.147
Authors: Gunnel Ragnarson Tennvall; J M Norlin; I Malmberg; A M Erlendsson; M Hædersdal Journal: Health Qual Life Outcomes Date: 2015-07-29 Impact factor: 3.186